Carla Rodriguez. Tirado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carla Rodriguez. Tirado has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Choushi Wang
Department of Molecular Biology UT Southwestern Medical Center 75390 Dallas TX USA
39 shared publications - Ping Mu
Department of Urology, Yale University School of Medicine
39 shared publications - Xiaoling Li
Department of Urology, School of Medicine, Yale University, New Haven, USA
39 shared publications - Ganesh V. Raj
Department of Urology UT Southwestern Medical Center 75390 Dallas TX USA
38 shared publications - Spencer Barnes
Bioinformatics Core Facility of the Lyda Hill Department of Bioinformatics UT Southwestern Medical Center 75390 Dallas TX USA
38 shared publications - Ariella B. Hanker
University of Texas Southwestern Medical Center 2 Department of Internal Medicine, Simmons Comprehensive Cancer Center Dallas, Texas
37 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Figure S1. ZNF397-deficiency has bifurcated effects on PCa with or without AR inhibition. Figure S2. The impact of ZNF397-deficiency on AR protein and AR cistrome. Figure S3. ZNF397 is required for the activation of canonical AR transcriptional program. Figure S4. ZNF397-KO impairs DHT-induced AR signaling activation. Figure S5. ZNF397-KO promotes multilineage and lineage plastic gene expression. Figure S6. ZNF397-KO promotes stem-like and EMT-like transcriptional programs. Figure S7. ZNF397-KO led to induction of TET2 downstream genes. Figure S8. ZNF397-KO promotes transcriptional activation of TET2 downstream genes. Figure S9. ZNF397-deficiency has bifurcated effects on AR-dependent vs AR-independent PCas. Figure S10. Targeting TET2-driven epigenetic rewiring to overcome resistance.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Figure S1. ZNF397-deficiency has bifurcated effects on PCa with or without AR inhibition. Figure S2. The impact of ZNF397-deficiency on AR protein and AR cistrome. Figure S3. ZNF397 is required for the activation of canonical AR transcriptional program. Figure S4. ZNF397-KO impairs DHT-induced AR signaling activation. Figure S5. ZNF397-KO promotes multilineage and lineage plastic gene expression. Figure S6. ZNF397-KO promotes stem-like and EMT-like transcriptional programs. Figure S7. ZNF397-KO led to induction of TET2 downstream genes. Figure S8. ZNF397-KO promotes transcriptional activation of TET2 downstream genes. Figure S9. ZNF397-deficiency has bifurcated effects on AR-dependent vs AR-independent PCas. Figure S10. Targeting TET2-driven epigenetic rewiring to overcome resistance.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S3. Significantly Enriched or Depleted Signaling Pathways in GSEA Analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S3. Significantly Enriched or Depleted Signaling Pathways in GSEA Analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S2. Differentially Expressed Genes in ZNF397-KO Cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S2. Differentially Expressed Genes in ZNF397-KO Cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S5. Lineage-Specific and AR Target Gene Signatures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S5. Lineage-Specific and AR Target Gene Signatures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S4. Candidate Resistance Driver Genes in ZNF397-KO Cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S4. Candidate Resistance Driver Genes in ZNF397-KO Cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S6 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S6 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S1. Significantly Altered AR ChIP-seq Peaks in ZNF397-KO Cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Table S1. Significantly Altered AR ChIP-seq Peaks in ZNF397-KO Cells
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Mapping the FOXA1 Interactome in ER+ Breast Cancer Cells Using Proximity Labeling Reveals Novel Interactions with the Orphan Nuclear Receptor NR2C2
Supplementary Figure S4. FOXA1 domain diagram (top) plus plasmid map (bottom) for the FLAG-tagged N-terminal FOXA1-miniTurbo construct in a lentiviral plasmid.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Mapping the FOXA1 Interactome in ER+ Breast Cancer Cells Using Proximity Labeling Reveals Novel Interactions with the Orphan Nuclear Receptor NR2C2
Supplementary Figure S4. FOXA1 domain diagram (top) plus plasmid map (bottom) for the FLAG-tagged N-terminal FOXA1-miniTurbo construct in a lentiviral plasmid.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Mapping the FOXA1 Interactome in ER+ Breast Cancer Cells Using Proximity Labeling Reveals Novel Interactions with the Orphan Nuclear Receptor NR2C2
Full MEME-AME results corresponding to summary plotted in Fig. 3F (CSV file).
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Mapping the FOXA1 Interactome in ER+ Breast Cancer Cells Using Proximity Labeling Reveals Novel Interactions with the Orphan Nuclear Receptor NR2C2
Full MEME-AME results corresponding to summary plotted in Fig. 3F (CSV file).